Float Short %

25.1

Margin Of Safety %

Put/Call OI Ratio

0.32

EPS Next Q Diff

0.23

EPS Last/This Y

0.64

EPS This/Next Y

1.35

Price

15.54

Target Price

37.5

Analyst Recom

1.08

Performance Q

45.74

Relative Volume

0.76

Beta

0.69

Ticker: SNDX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	SNDX	15.73	0.28	0.39	48775
2025-08-18	SNDX	15.87	0.21	0.17	40070
2025-08-19	SNDX	15.4	0.21	0.85	41170
2025-08-20	SNDX	15.73	0.22	0.22	41847
2025-08-21	SNDX	15.85	0.26	1.50	45710
2025-08-22	SNDX	16.25	0.26	0.08	45819
2025-08-25	SNDX	15.66	0.26	0.99	46768
2025-08-26	SNDX	15.85	0.27	0.04	46958
2025-08-27	SNDX	16.28	0.31	0.07	41892
2025-08-28	SNDX	16.32	0.32	0.46	41984
2025-08-29	SNDX	16.33	0.31	0.08	43298
2025-09-02	SNDX	16.11	0.31	0.19	43695
2025-09-03	SNDX	16.11	0.31	0.08	43692
2025-09-04	SNDX	16.2	0.31	0.09	43754
2025-09-05	SNDX	17.05	0.31	0.00	43948
2025-09-08	SNDX	16.34	0.32	0.27	43272
2025-09-09	SNDX	15.93	0.32	0.08	43590
2025-09-10	SNDX	15.74	0.32	0.03	43895
2025-09-11	SNDX	16.36	0.32	0.08	44053
2025-09-12	SNDX	15.54	0.32	2.82	44246
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	SNDX	15.73	28.1	23.9	-3.09
2025-08-18	SNDX	15.88	28.1	48.6	-3.09
2025-08-19	SNDX	15.40	28.1	63.8	-3.09
2025-08-20	SNDX	15.73	28.1	43.0	-3.09
2025-08-21	SNDX	15.85	28.1	49.5	-3.09
2025-08-22	SNDX	16.25	28.1	41.7	-3.09
2025-08-25	SNDX	15.65	28.1	66.3	-3.09
2025-08-26	SNDX	15.85	28.1	47.3	-3.09
2025-08-27	SNDX	16.27	28.1	41.4	-3.09
2025-08-28	SNDX	16.32	28.1	50.5	-3.09
2025-08-29	SNDX	16.32	28.1	57.4	-3.09
2025-09-02	SNDX	16.11	28.1	57.4	-3.09
2025-09-03	SNDX	16.11	28.1	189.2	-3.09
2025-09-04	SNDX	16.20	28.1	188.3	-3.09
2025-09-05	SNDX	17.04	28.1	179.2	-3.09
2025-09-08	SNDX	16.33	28.1	196.8	-3.08
2025-09-09	SNDX	15.93	28.1	193.8	-3.08
2025-09-10	SNDX	15.73	28.1	191.5	-3.08
2025-09-11	SNDX	16.37	28.1	181.3	-3.08
2025-09-12	SNDX	15.54	28.1	198.7	-3.08
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	SNDX	0.28	6.96	28.95
2025-08-18	SNDX	0.28	4.89	28.95
2025-08-19	SNDX	-1.31	4.89	28.68
2025-08-20	SNDX	-1.66	4.89	28.68
2025-08-21	SNDX	-1.66	4.89	28.68
2025-08-22	SNDX	-1.66	4.89	28.68
2025-08-25	SNDX	-1.66	6.62	28.68
2025-08-26	SNDX	-1.66	6.62	28.68
2025-08-27	SNDX	-1.66	6.62	24.73
2025-08-28	SNDX	-1.66	6.62	24.73
2025-08-29	SNDX	-1.66	6.62	24.73
2025-09-02	SNDX	-1.66	6.19	24.72
2025-09-03	SNDX	-1.67	6.19	24.72
2025-09-04	SNDX	-1.67	6.19	24.72
2025-09-05	SNDX	-1.67	6.19	24.72
2025-09-08	SNDX	-1.40	6.32	24.72
2025-09-09	SNDX	-6.59	6.32	24.72
2025-09-10	SNDX	-6.59	6.32	24.72
2025-09-11	SNDX	-6.59	6.32	25.10
2025-09-12	SNDX	-6.59	6.32	25.10
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.83

Avg. EPS Est. Current Quarter

-0.7

Avg. EPS Est. Next Quarter

-0.6

Insider Transactions

-6.59

Institutional Transactions

6.32

Beta

0.69

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-69.9

Target Price

37.5

P/E

Forward P/E

PEG

P/S

17.13

P/B

8.5

P/Free Cash Flow

EPS

-3.9

Average EPS Est. Cur. Y

-3.08

EPS Next Y. (Est.)

-1.73

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-428.48

Relative Volume

0.76

Return on Equity vs Sector %

-237.7

Return on Equity vs Industry %

-224.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

198.7

Syndax Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 270

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

stock quote shares SNDX – Syndax Pharmaceuticals, Inc. Stock Price stock today

news today SNDX – Syndax Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SNDX – Syndax Pharmaceuticals, Inc. yahoo finance google finance

stock history SNDX – Syndax Pharmaceuticals, Inc. invest stock market

stock prices SNDX premarket after hours

ticker SNDX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SNDX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y